| dc.contributor | Madrid Díaz, Guillermo Adolfo | |
| dc.contributor | Ardila, Gerardo | |
| dc.creator | Moreno Araque, Jeimy Lorena | |
| dc.creator | Ordóñez Bastidas, Edgar Andrés | |
| dc.date.accessioned | 2021-07-23T22:09:17Z | |
| dc.date.accessioned | 2022-09-22T13:46:46Z | |
| dc.date.available | 2021-07-23T22:09:17Z | |
| dc.date.available | 2022-09-22T13:46:46Z | |
| dc.date.created | 2021-07-23T22:09:17Z | |
| dc.identifier | https://repository.urosario.edu.co/handle/10336/31903 | |
| dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3432418 | |
| dc.description.abstract | Objective: To identify lactate as a predictor of clinical outcomes in care postoperative of patients with resection of brain tumors Design. Observational prospective clinical cohort study. 224 were included patients in postoperative resection of brain tumors admitted to the ICU. The overall in-hospital mortality rate at 28 days was 1.3%. The Lactate levels in the group of patients who died were higher 3.70 (IQR 3.75) vs 1.60 (IQR 1.30), all patients who died at 28 days, they presented hyperlactatemia (p = 0.044). Of all patients, 35.7% had an elevated lactate level, while 64.3% had an elevated lactate low or normal serum. Patients with high-grade tumors, and volumes high tumor levels, presented higher levels of lactate. They were not found differences between the length of hospital stay and the length of stay in the unit of intensive care among patients with hyperlactatemia and low or low lactate normal, as well as there were no differences between these two groups related with readmission to ICU, re-intubation and re-intervention. Conclusion: Patients admitted to the ICU postoperatively for resection of brain tumors have low mortality at 28 days, however 100% of the deceased patients had hyperlactatemia. The clinical outcomes evaluated in ICU they do not correlate with hyperlactatemia, with the exception of rebleeding. We consider that early postoperative lactate measurement could relate to bad outcomes, however a sample is required higher | |
| dc.language | spa | |
| dc.publisher | Universidad del Rosario | |
| dc.publisher | Especialización en Medicina Crítica y Cuidado Intensivo | |
| dc.publisher | Escuela de Medicina y Ciencias de la Salud | |
| dc.rights | info:eu-repo/semantics/embargoedAccess | |
| dc.rights | Restringido (Temporalmente bloqueado) | |
| dc.rights | EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma.
PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe.
EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización.
--------------------------------------
POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos. | |
| dc.source | Estadísticas del tumor cerebral | Asociación Estadounidense del Tumor Cerebral [Internet]. [cited 2018 Feb 24]. Available from: http://www.abta.org/about-us/news/brain-tumor-statistics/ | |
| dc.source | ABTA. Brain Tumor Statistics [Internet]. Brain Tumor Statistics. Available from: http://www.abta.org/about-us/news/brain-tumor-statistics/ | |
| dc.source | Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol [Internet]. 2017;19(suppl_5):v1–88. Available from: http://academic.oup.com/neuro-oncology/article/19/suppl_5/v1/4596648 | |
| dc.source | Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de Cáncer en Colombia 2007-2011 [Internet]. Vol. 1, Instituto Nacional De Cancerologia. 2015. 148 p. Available from: http://www.cancer.gov.co/files/libros/archivos/incidencia1.pdf | |
| dc.source | DIEA. Anuario estadístico. 2016;198. Available from: www.mgap.gub.uy | |
| dc.source | De La Garza-Ramos R, Kerezoudis P, Tamargo RJ, Brem H, Huang J, Bydon M. Surgical complications following malignant brain tumor surgery: An analysis of 2002-2011 data. Clin Neurol Neurosurg [Internet]. 2016;140:6–10. Available from: http://dx.doi.org/10.1016/j.clineuro.2015.11.005 | |
| dc.source | Helal AE, Abouzahra H, Fayed AA, Rayan T, Abbassy M. Socioeconomic restraints and brain tumor surgery in low-income countries. Neurosurg Focus. 2018;45(4):1–5. | |
| dc.source | Mariappan R, Venkatraghavan L, Vertanian A, Agnihotri S, Cynthia S, Reyhani S, et al. Serum lactate as a potential biomarker of malignancy in primary adult brain tumours. J Clin Neurosci [Internet]. 2015;22(1):144–8. Available from: http://dx.doi.org/10.1016/j.jocn.2014.06.005 | |
| dc.source | Jianrong Lua, Ming Tanb and QC. The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism. 2016;356(2):156–64. | |
| dc.source | Choi SYC, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: A regulatory, immunosuppressive metabolite? J Pathol. 2013;230(4):350–5. | |
| dc.source | Barros LF, Deitmer JW. Glucose and lactate supply to the synapse. Brain Res Rev [Internet]. 2010;63(1–2):149–59. Available from: http://dx.doi.org/10.1016/j.brainresrev.2009.10.002 | |
| dc.source | Gunnerson KJ, Saul M, He S, Kellum JA. Lactate versus non-lactate metabolic acidosis: A retrospective outcome evaluation of critically ill patients. Crit Care. 2006;10(1):1–9. | |
| dc.source | Lee Y, Kim W, Yoo J, Jung H, Min T. Correlation between regional tissue perfusion saturation and lactate level during cardiopulmonary bypass. Korean Journal of Anesthesiology. 2018;71(5):361-367. | |
| dc.source | Kraut JA, Madias NE. Lactic Acidosis. N Engl J Med [Internet]. 2014;371(24):2309–19. Available from: http://www.nejm.org/doi/10.1056/NEJMra1309483 | |
| dc.source | Mesquida J, Borrat X, Lorente JA, Masip J, Baigorri F. Objetivos de la reanimación hemodinámica. Med Intensiva. 2011;35(8):499–508. | |
| dc.source | Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Vol. 45, Critical Care Medicine. 2017. 486-552 p. | |
| dc.source | Levy B, Desebbe O, Montemont C, Gibot S. Increased aerobic glycolysis through β2 stimulation is a common mechanism involved in lactate formation during shock states. Shock. 2008;30(4):417–21. | |
| dc.source | Okorie ON, Dellinger P. Lactate: Biomarker and Potential Therapeutic Target. Crit Care Clin. 2011;27(2):299–326. | |
| dc.source | Bertram JS. The molecular biology of cancer. Mol Aspects Med. 2000;21:167–223. | |
| dc.source | Poff A, Koutnik AP, Egan KM, Sahebjam S, D’Agostino D, Kumar NB. Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma. Semin Cancer Biol [Internet]. 2019;56:135–48. Available from: http://dx.doi.org/10.1016/j.semcancer.2017.12.011 | |
| dc.source | Vander Heiden MG, Cantley LC, ompson CB. Understanding the Warburg effect: e metabolic requirements of cell proliferation. Science 2009;324:1029-33 | |
| dc.source | Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. International Journal of Radiation Biology. 2019;95(7):912-919. | |
| dc.source | Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch BJ, et al. Metabolic Targeting of Lactate Efflux by Malignant Glioma Inhibits Invasiveness and Induces Necrosis: An In Vivo Study. Neoplasia [Internet]. 2011;13(7):620–32. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1476558611800266 | |
| dc.source | Walenta S, Salameh a, Lyng H, Evensen JF, Mitze M, Rofstad EK, et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol. 1997;150(2):409–15. | |
| dc.source | Bharadwaj S, Venkatraghavan L, Mariappan R, Ebinu J, Meng Y, Khan O, et al. Serum lactate as a potential biomarker of non-glial brain tumors. J Clin Neurosci [Internet]. 2015;22(10):1625–7. Available from: http://dx.doi.org/10.1016/j.jocn.2015.05.009 | |
| dc.source | Cata JP, Bhavsar S, Hagan KB, Arunkumar R, Grasu R, Dang A, et al. Intraoperative serum lactate is not a predictor of survival after glioblastoma surgery. J Clin Neurosci [Internet]. 2017;43(2017):224–8. Available from: http://dx.doi.org/10.1016/j.jocn.2017.05.004 | |
| dc.source | de Smalen PP, van Ark TJ, Stolker RJ, Vincent AJPE, Klimek M. Hyperlactatemia After Intracranial Tumor Surgery Does Not Affect 6-Month Survival. J Neurosurg Anesthesiol [Internet]. 2019;00(00):1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30913172%0Ahttp://Insights.ovid.com/crossref ?an=00008506-900000000-99164 | |
| dc.source | Dong Z, Zhong X, Lei Q, Chen F, Cui H. Transcriptional activation of SIRT6 via FKHRL1/FOXO3a inhibits the Warburg effect in glioblastoma cells. Cell Signal [Internet]. 2019;60(2):100–13. Available from: https://doi.org/10.1016/j.cellsig.2019.04.009 | |
| dc.source | Kohli-Seth R, Mukkera SR, Leibowitz AB, Nemani N, Oropello JM, Manasia A, et al. Frequency and Outcomes of Hyperlactatemia After Neurosurgery: A Retrospective Analysis. ICU Dir. 2011;2(6):211–4. | |
| dc.source | Okorie ON, Dellinger P. Lactate: Biomarker and potential therapeutic target. Crit Care Clin 2011;27:299-326. | |
| dc.source | Phypers B, Pierce JMT. Lactate physiology in health and disease. Contin Educ Anaesthesia, Crit Care Pain [Internet]. 2006;6(3):128–32. Available from: http://dx.doi.org/10.1093/bjaceaccp/mkl018 | |
| dc.source | RomanoID D, Deiner S, Cherukuri A, Boateng B, Shrivastava R, Mocco J, et al. Clinical impact of intraoperative hyperlactatemia during craniotomy. PLoS One [Internet]. 2019;14(10):1–12. Available from: https://doi.org/10.1371/journal.pone.0224016 | |
| dc.source | Ioannoni E, Grande G, Olivi A, Antonelli M, Caricato A, Montano N. Factors affecting serum lactate in patients with intracranial tumors-A report of our series and review of the literature. Surg Neurol Int • [Internet]. 2020 [cited 2020 Nov 5];11(39):1–5. Available from: www.surgicalneurologyint.com | |
| dc.source | Shih CC, Lee TS, Tsuang FY, Lin PL, Cheng YJ, Cheng HL, Wu CY. Pretreatment serum lactate level as a prognostic biomarker in patients undergoing supratentorial primary brain tumor resection. Oncotarget. 2017 Jun 29;8(38):63715-63723. doi: 10.18632/oncotarget.18891. PMID: 28969023; PMCID: PMC5609955. | |
| dc.source | instname:Universidad del Rosario | |
| dc.source | reponame:Repositorio Institucional EdocUR | |
| dc.subject | Correlación niveles de lactato en desenlace post operatorio de pacientes con resección de tumores cerebrales | |
| dc.subject | Niveles de lactato como predictor de desenlace clínico | |
| dc.subject | Hiperlactatemia asociada a resección quirúrgica de tumores cerebrales | |
| dc.subject | Análisis de niveles de lactato en pacientes con resección de tumores cerebrales | |
| dc.title | Lactato postoperatorio como predictor de desenlaces clínicos en el paciente con resección de tumores cerebrales | |
| dc.type | masterThesis | |
